Pharmacovigilance of antimalarial treatment in Africa: is it possible?
about
Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trialThe safety of amodiaquine use in pregnant womenPregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countriesDesigning adverse event forms for real-world reporting: participatory research in UgandaRare, serious, and comprehensively described suspected adverse drug reactions reported by surveyed healthcare professionals in UgandaDihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposalsMobile phone text messaging: tool for malaria control in Africa.Pharmacovigilance practices for better healthcare delivery: knowledge and attitude study in the national malaria control programme of India.Influences on participant reporting in the World Health Organisation drugs exposure pregnancy registry; a qualitative studyAssessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring.Exposure to anti-malarial drugs and monitoring of adverse drug reactions using toll-free mobile phone calls in private retail sector in Sagamu, Nigeria: implications for pharmacovigilanceProspective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and TanzaniaPharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire.Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia.The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya.A prospective study of adverse drug reactions to artemisinin-based combination therapy in a tertiary care hospital in India.Experiences and Lessons From Implementing Cohort Event Monitoring Programmes for Antimalarials in Four African Countries: Results of a Questionnaire-Based Survey.Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malariaAnti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western SenegalSafety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria settingSafety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.Monitoring antimalarial safety and tolerability in clinical trials: a case study from UgandaNeglected tropical diseases in Uganda: the prospect and challenge of integrated control.Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural TanzMonitoring and evaluation of malaria in pregnancy - developing a rational basis for control.Inpatient mortality in children with clinically diagnosed malaria as compared with microscopically confirmed malaria.Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combinationApplication of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected childrenSafety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire.Toxicity of the antimalarial artemisinin and its dervatives.In vitro studies on the sensitivity pattern of Plasmodium falciparum to anti-malarial drugs and local herbal extractsSafety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study.Artesunate- and amodiaquine-associated extrapyramidal reactions: a series of 49 cases in VigiBase™.Establishing pharmacovigilance programs in resource-limited settings: the example of treating malaria.
P2860
Q24597403-3B5D126F-5D75-412E-98AA-AAF7FD48BB65Q28255205-C3CCD561-0FE0-4BEF-983C-2D65A1CB9486Q28473631-5C43AFF2-95B3-4B86-B00A-D1CD769E5312Q28481812-48C18F70-98DB-4136-AA21-99308D4C783BQ28546673-93AC481E-716F-44C8-AD61-468658C9F318Q33516563-334B0C68-CAB9-4FF7-81AB-B61A538F2FEBQ33635019-0B754A05-3E9E-4F4E-8EFA-567750E3028DQ33678483-0F2B3EDE-0E4F-44EB-ABD3-0D6EDCDE9FB7Q33922071-08B7FD77-99D8-490B-9A81-0E4A4BC7DDFCQ34169722-77B9A8CA-C4C5-4915-B439-3553738D3914Q34273540-6BA2C2A7-7A46-4AC3-B941-932A74A88908Q34499470-C2FEBE1C-6BC5-4CE7-8E55-33594CDF9E60Q34716441-DBAB8835-A364-4CEA-A7CE-45176FF411B4Q35183422-A1E920BC-AD39-4983-AFAC-B98F125D4442Q35519260-304373BF-50A0-4E98-9B4A-1F01A325CCABQ35582624-EC2EF9D4-DF07-46A1-9A17-AFDB4CC02F87Q35676996-499941CC-75E1-41A7-9EDF-495F5E2FBEE9Q35842358-00721527-5D62-48BF-8A60-983E65144BC2Q35890432-3452323A-9120-4D7D-9E57-10B92174977FQ36171629-20791F3A-43D5-487D-94FB-26FC213AF248Q36184868-B96D04DE-A4A1-42B1-963A-0D2632BF47B5Q36544502-C91939E8-0DF2-4063-A74B-AE1986ED297EQ36687437-1B15AE3A-08E5-49BB-9FCA-12CFA5F89416Q36739784-3DC20197-4AE9-4A22-90D5-464A5C69FD3FQ36766577-DA533580-A068-49F4-BFEF-B42F46191BC4Q36934562-42CC7035-EA03-4339-AE41-F7145FA70222Q36959519-61639A09-80AE-4650-A87A-4BAA307A23C8Q37009500-939CB1C7-CA30-400E-940D-8EAFACF153FDQ37018621-3ACC0AD3-B89C-413D-AAD0-EC9B625F554FQ37023952-FE7D8054-3288-4FE5-9CEB-45075BF3B618Q37119572-24699F3F-4DEB-421D-84F5-22D3146A9294Q37182220-7A5D4206-CD14-4E8D-943D-6917B5B76427Q37278622-A5A6D5AE-A4AC-46CB-B5BA-96E3C3E367CCQ37460745-CA759E79-8334-4055-A473-4155BE4CA4FDQ37555147-B9C4CB35-19BF-42D1-83F0-AE4B667826B5Q37693152-4CD87883-0D39-4431-9D5D-B84C11FAB24BQ37717358-AB8951B4-FAD5-4602-97B7-F2E0C9A6FCEBQ41926058-1F4CCD5E-DACD-4C1D-8BB0-6A0049A11FB3Q44432479-82BCF526-5B5F-42B2-BFEF-BFECE9DCB6BBQ47995732-94F01FC4-8566-492A-9C76-07A19A2E0441
P2860
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@ast
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@en
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@nl
type
label
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@ast
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@en
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@nl
prefLabel
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@ast
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@en
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@nl
P2860
P356
P1433
P1476
Pharmacovigilance of antimalarial treatment in Africa: is it possible?
@en
P2093
Ambrose O Talisuna
P2860
P2888
P356
10.1186/1475-2875-5-50
P577
2006-06-16T00:00:00Z
P5875
P6179
1020292613